References
- Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis 2015;60(4):627–638.
- Zahid M, Mangin P, Loyau S, Hechler B, Billiald P, Gachet C, Jandrot-Perrus M. The future of glycoprotein VI as an antithrombotic target. J Thromb Haemost 2012;10(12):2418–2427.
- Al-Tamimi M, Tan CW, Qiao J, Pennings GJ, Javadzadegan A, Yong AS, et al. Pathologic shear triggers shedding of vascular receptors: A novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels. Blood 2012;119(18):4311–4320.
- Al-Tamimi M, Arthur JF, Gardiner E, Andrews RK. Focusing on plasma glycoprotein VI. Thromb Haemost 2012;107(4):648–655.
- Trevillyan JM, Cheng AC, Hoy J. Abacavir exposure and cardiovascular risk factors in HIV-positive patients with coronary heart disease: A retrospective case–control study. Sex Health 2013;10(2):97–101.
- Westhorpe CL, Maisa A, Spelman T, Hoy JF, Dewar EM, Karapanagiotidis S, et al. Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV-positive individuals. Immunol Cell Biol 2014;92(2):133–138.
- Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 2009;20(3):143–149.
- Egan K, Dillon A, Dunne E, Kevane B, Galvin Z, Maguire P, Kenny D, Stewart S, Ainle FN. Increased soluble GPVI levels in cirrhosis: Evidence for early in vivo platelet activation. J Thromb Thrombolysis 2016.
- Aota T, Naitoh K, Wada H, Yamashita Y, Miyamoto N, Hasegawa M, et al. Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban. Int J Hematol 2014;100(5):450–456.
- Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, et al. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis 2013;57(1):112–121.
- Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost 2007;5(7):1530–1537.
- Friedrich BM, Murray JL, Li G, Sheng J, Hodge TW, Rubin DH, O’Brien WA, Ferguson MR. A functional role for ADAM10 in human immunodeficiency virus type-1 replication. Retrovirology 2011;8:32.
- Lee JH, Wittki S, Brau T, Dreyer FS, Krätzel K, Dindorf J, et al. HIV Nef, paxillin, and Pak1/2 regulate activation and secretion of TACE/ADAM10 proteases. Mol Cell 2013;49(4):668–679.
- Schulz C, Penz S, Hoffmann C, Langer H, Gillitzer A, Schneider S, et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol 2008;103(4):356–367.
- Bigalke B, Potz O, Kremmer E, Geisler T, Seizer P, Puntmann VO, et al. Sandwich immunoassay for soluble glycoprotein VI in patients with symptomatic coronary artery disease. Clin Chem 2011;57(6):898–904.